|Semotus Solutions Co-Develops KINETIDEX 2.0: Industry Leading Dosing Tool Assists Doctor in Critical Dosing Decisions
|SAN JOSE, Calif., February 5, 2001-Semotus Solutions(AMEX: DLK), a market leading wireless application service provider (w-ASP) and infrastructure architect, today announced the release of KINETIDEX 2.0. Jointly developed, the product will be marketed by MICROMEDEX, a division of Thomson Healthcare. KINETIDEX 2.0 is currently available for purchase.
Simkin, Inc. (www.simkinrx.com), a wholly owned subsidiary of Semotus Solutions, co-developed KINETIDEX 2.0 along with MICROMEDEX (www.micromedex.com). KINETIDEX 2.0 is a CD-ROM and/or network-based program that relies on elaborate mathematical equations to enable pharmacists to calculate complicated drug doses easily and accurately. The program operates within a Windows platform in a quick, easy-to-use format that presents all of the information on just two screens.
"We are pleased to extend our healthcare offerings for a product as crucial to the healthcare community as KINETIDEX 2.0," said Dr. Dan Robinson, President of Simkin, Inc. "KINETIDEX 2.0 is another quality solution in our next generation of healthcare products and services, solutions that will help to transform the industry as a whole.”
"KINETIDEX 2.0 is an important new development for hospital pharmacists,"
said Dr. Gina Moore, Senior Product Manager of Drug Information products at MICROMEDEX. “The ability to correctly dose medications in a quick and efficient manner will ultimately save hospitals money while simultaneously improving patient care.”
KINETIDEX 2.0 will replace CAPCIL kinetics in the Simkin product line. Simkin will continue to offer Medication Usage Evaluation (MUE) and Adverse Drug Reaction (ADR) management as separate programs.
To purchase KINETIDEX 2.0, or for more information, contact MICROMEDEX at
About Semotus Solutions – The Wireless Architects
Semotus Solutions is a market-leading wireless infrastructure provider delivering end-to-end wireless solutions to its enterprise customers. Semotus Solutions’ patented technology and real-time delivery systems enable enterprise customers and employees to utilize any wireless device to receive and respond to critical data 24x7x365.
Semotus Solutions is leveraging its core XpressLink technology across high demand, vertical markets, including finance, medical and the mobile workforce, to allow for the use of any wireless device and any digital communication language to push and pull data on demand. This technology produced the wireless market’s first truly integrated enterprise product, Global Market Pro, which is Semotus Solutions’ advanced, fully customizable wireless application for the financial professional. Global Market Pro was co-developed with The Chase Manhattan Bank and is employed by individuals and institutions throughout the financial community.
The Company serves a portfolio of marquee customers, including AOL, AT&T, Bank of America, Dow Jones, Citibank, EDS, Motorola and Qualcomm.
Semotus Solutions is headquartered in San Jose, Calif., with research facilities located in Vancouver, British Columbia and offices in Chicago, Philadelphia, New Jersey and Florida. For more information: http://www.semotus.com.
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “intends,” “believes” and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, successful integration of acquisitions, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.